Stay updated on Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now displays a 403 Forbidden error, blocking access to the study record. This change represents an access restriction rather than modification of the study content visible on the page.SummaryDifference19%

- Check33 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new release of the site's rendering/template. This change is a backend/version update and does not alter the displayed study details or other content.SummaryDifference0.1%

- Check40 days agoChange DetectedNew update timestamps for 2026 were added and older 2025 timestamps were removed in the Study Record Dates, reflecting routine record maintenance rather than changes to study design or results.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a small maintenance update to the study record.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page revision was updated from `v3.6.4` to `v3.6.5`, indicating a newer version of the page content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.